Premium
Testosterone treatment prevents spinal cord injury‐induced bone loss in male rats
Author(s) -
Beggs Luke Allen,
Beck Darren T,
Conover Christine F,
Ye Fan,
Combs Sarah M,
Miller Julie R,
Balaez Alexander,
Neuville Kathleen G,
Wronski Thomas J,
Bose Prodip,
Borst Stephen E,
Yarrow Joshua F
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.941.4
Subject(s) - spinal cord injury , medicine , cancellous bone , trabecular bone , spinal cord , urology , osteoporosis , anatomy , psychiatry
Our objective was to determine if testosterone enanthate (TE) attenuates bone loss in a rodent mid‐thoracic contusion spinal cord injury (SCI) model. Three month old male Sprague Dawley rats received Sham surgery (T8 laminectomy) + vehicle (V), 150 kdyne SCI + V (SCI 150), 250 kdyne SCI + V (SCI 250), SCI 250 + Low TE (2mg/week), or SCI 250 + High TE (7mg/week). SCI was induced via Infinite Horizons Impactor. Animals were sacrificed 3 weeks after injury. Bone structural parameters were assessed via histomorphometry at the proximal tibial metaphysis. SCI induced intensity‐dependent structural deficits, which were prevented by TE in a dose‐dependent manner. TE may provide treatment for SCI‐induced bone loss, thereby reducing the risk of fragility fractures.Sham (a) SCI 150 (b) SCI 250 (c) SCI 250 + Low T (d) SCI 250 + High T (e)Cancellous Bone Volume (%) 4.6 ± 0.9 c* 2.3 ± 0.3 0.8 ± 0.2 a*,e* 3.5 ± 0.5 4.6 ± 0.9 c*Trabecular Width (μm) 14.6 ± 1.1 c 11.8 ± 1.1 10.7 ± 1.1 a 12.5 ± 0.4 13.0 ± 0.5 Trabecular Number (#/mm) 3.7 ± 0.6 c* 2.4 ± 0.2 0.9 ± 0.2 a*,d,e* 3.3 ± 0.4 c 4.1 ± 0.7 c*Trabecular Separation (μm) 463 ± 189 c* 419 ± 36 c 1520 ± 322 a*,b,d*,e* 384 ± 106 c* 322 ± 75 c*Values are Means ± SE of n = 4–9/group. Letters a‐e indicate differences from respectively labeled groups at p < 0.05 or * p < 0.01.Work was supported by Veterans Department CDA‐2 to JFY.